Clinical Trials Browser

Neoplasm Metastasis × Capecitabine × 1 year × Clear all

NCT07007559 2026-06-05

ASPEN-09-03

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06247995 2026-05-27

NeoB-Cap1

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT07432295 2026-05-14

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT05803382 2026-05-13

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Phase 2 Recruiting

Neoplasm Metastasis

NCT00905047 2026-03-13

COLOCROSS

Phase 3 Completed

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT04333706 2026-03-10

EMPOWER

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT07407465 2026-02-17

CHIMERA

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03869892 2025-12-22

SOLSTICE

Phase 3 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase 2 Recruiting

Gastrointestinal

Appendiceal Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04701281 2025-09-18

SYS-CAPLIOX

Phase 1/2 Terminated

Neoplasm Metastasis

NCT00680901 2025-08-07

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Phase 3 Completed

545 enrolled 24 charts

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms